IP Library Granted Patent US 8,377,896
Granted Patent B2
US 8,377,896 · App. 13/044,226 · Granted Feb 19, 2013

Antibacterial 4,6-substituted 6′, 6″ and 1 modified aminoglycoside analogs

Inventors: Michael T. Migawa (Carlsbad, CA); Xiaojing Wang (Foster City, CA); Eric E. Swayze (Encinitas, CA); Richard H. Griffey (Vista, CA)
Assignee: Isis Pharmaceuticals, Inc
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,896
App. No.
13/044,226
Granted
Feb 19, 2013
Kind
B2
Abstract

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.

Claims (25)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

each R 1 and R 2 is, independently, H or an amino protecting group;

each R 3 is, independently, H or a hydroxyl protecting group;

R 4 and R 5 are each, independently, H, amino protecting group, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl or substituted C 2 -C 12 alkynyl;

Q 1 is cyano, azido, or NR 8 R 9 ;

Q 2 is NH 2 or N(CH 2 R 6 )R 7 ;

R 6 and R 7 are each, independently, H, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 7 -C 9 alicyclic radical, substituted C 7 -C 9 alicyclic radical, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl or substituted C 2 -C 12 alkynyl; and

R 8 and R 9 are each, independently, H, CN, C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 7 -C 9 alicyclic radical, substituted C 7 -C 9 alicyclic radical, C 2 -C 12 alkenyl, substituted C 2 -C 12 alkenyl, C 2 -C 12 alkynyl or substituted C 2 -C 12 alkynyl;

wherein said substituents are each, independently, NJ 1 J 2 or C 5 -C 20 aryl; and

wherein each J 1 and J 2 is, independently, H, C 1 -C 12 alkyl or C 5 -C 20 aryl.

2. The compound of claim 1 wherein each R 1 and R 2 is H.

3. The compound of claim 1 wherein each R 3 is H.

4. The compound of claim 1 wherein Q 1 is NR 8 R 9 .

5. The compound of claim 4 wherein one of said R 8 and R 9 is H and the other of said R 8 and R 9 is C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 7 -C 9 alicyclic radical or substituted C 7 -C 9 alicyclic radical.

6. The compound of claim 1 wherein Q 1 is NH 2 .

7. The compound of claim 6 wherein R 7 is H or C 1 -C 12 alkyl.

8. The compound of claim 6 wherein R 6 is C 1 -C 12 alkyl, substituted C 1 -C 12 alkyl, C 7 -C 9 alicyclic radical or substituted C 7 -C 9 alicyclic radical.

9. The compound of claim 8 wherein R 6 is substituted C 1 -C 12 alkyl.

10. The compound of claim 1 wherein one of R 4 and R 5 is H and the other of R 4 and R 5 is C 1 -C 12 alkyl or substituted C 1 -C 12 alkyl.

11. The compound of claim 1 wherein each of R 1 , R 4 and R 5 are H.

12. The compound of claim 1 wherein Q 1 is azido or cyano.

13. The compound of claim 1 having the configuration:

14. A method of treating a bacterial infection in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2011
From: MIGAWA, MICHAEL T.; WANG, XIAOJING; SWAYZE, ERIC E.; GRIFFEY, RICHARD H.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 026464/0462 →
Continuity (3)
Continuation PCTUS2009056391 · Sep 9, 2009
Provisional Application 61095670 · Sep 10, 2008
Related Publication 20110245476A1 · Oct 6, 2011